Cellares, the contract drugmaker known for its cell therapy factory-in-a-box, will expand its operations to Europe after ...

Glioblastoma remains one of the most challenging solid tumors to treat due to its highly immunosuppressive tumor microenvironment.

The first half of 2025 has been a notable one for Cellares. The cell therapy manufacturer operates its first commercial-scale Integrated Development and Manufacturing Organization Smart Factory in ...

Made Scientific marked a milestone Aug. 13 as it cut the ribbon on its new cell therapy manufacturing facility and headquarters in Princeton. A number of government officials, industry leaders and ...

Lumacyte CEO on how real-time insight is driving down manufacturing failures and opening doors for more patients.

A little over a year after winning manufacturing certification for its cell therapy factory-in-a-box, South San Francisco’s Cellares has passed another major production milestone. Cellares’ automated ...

The AMT designation gives Cellares’ clients using the Cell Shuttle priority review with the FDA leading to accelerated regulatory filings SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Cellares, the ...

Technology Adoption Program (TAP) program success demonstrates the ability of Cellares’ IDMO Smart Factory to automate, lower costs and scale out manufacturing for Cabaletta Bio’s clinical-stage CAR T ...

PRINCETON, N.J. and CHICAGO, Sept. 30, 2025 /PRNewswire/ -- Made Scientific, a leading cell therapy contract development and manufacturing organization (CDMO) and Syenex, a synthetic biology company ...

- Joint venture will aim to develop a cell therapy manufacturing platform through robotics and will offer access to startups and academic institutions - In the pharmaceutical industry, the ...

RADNOR, PA & PHILADELPHIA, PA — Avantor, Inc. (NYSE: AVTR) has entered into a strategic partnership with BlueWhale Bio, a commercial-stage biotechnology firm focused on improving immune cell therapy ...

CAR-T therapies have proven their curative potential, but cell therapy developers continue to face challenges related to manufacturing complexities, costs, scalability, regulatory compliance, and ...